Neuroprotective Effect of Natural Indole and β-carboline Alkaloids against Parkinson’s Disease: An Overview

Feigin, V.L.; Nichols, E.; Alam, T.; Bannick, M.S.; Beghi, E.; Blake, N.; Culpepper, W.J.; Dorsey, E.R.; Elbaz, A.; Ellenbogen, R.G.; Fisher, J.L.; Fitzmaurice, C.; Giussani, G.; Glennie, L.; James, S.L.; Johnson, C.O.; Kassebaum, N.J.; Logroscino, G.; Marin, B.; Mountjoy-Venning, W.C.; Nguyen, M.; Ofori-Asenso, R.; Patel, A.P.; Piccininni, M.; Roth, G.A.; Steiner, T.J.; Stovner, L.J.; Szoeke, C.E.I.; Theadom, A.; Vollset, S.E.; Wallin, M.T.; Wright, C.; Zunt, J.R.; Abbasi, N.; Abd-Allah, F.; Abdelalim, A.; Abdollahpour, I.; Aboyans, V.; Abraha, H.N.; Acharya, D.; Adamu, A.A.; Adebayo, O.M.; Adeoye, A.M.; Adsuar, J.C.; Afarideh, M.; Agrawal, S.; Ahmadi, A.; Ahmed, M.B.; Aichour, A.N.; Aichour, I.; Aichour, M.T.E.; Akinyemi, R.O.; Akseer, N.; Al-Eyadhy, A. Al-Shahi Salman, R.; Alahdab, F.; Alene, K.A.; Aljunid, S.M.; Altirkawi, K.; Alvis-Guzman, N.; Anber, N.H.; Antonio, C.A.T.; Arabloo, J.; Aremu, O.; Ärnlöv, J.; Asayesh, H.; Asghar, R.J.; Atalay, H.T.; Awasthi, A.; Ayala Quintanilla, B.P.; Ayuk, T.B.; Badawi, A.; Banach, M.; Banoub, J.A.M.; Barboza, M.A.; Barker-Collo, S.L.; Bärnighausen, T.W.; Baune, B.T.; Bedi, N.; Behzadifar, M.; Behzadifar, M.; Béjot, Y.; Bekele, B.B.; Belachew, A.B.; Bennett, D.A.; Bensenor, I.M.; Berhane, A.; Beuran, M.; Bhattacharyya, K.; Bhutta, Z.A.; Bi-adgo, B.; Bijani, A.; Bililign, N.; Bin Sayeed, M.S.; Blazes, C.K.; Brayne, C.; Butt, Z.A.; Campos-Nonato, I.R.; Cantu-Brito, C.; Car, M.; Cárdenas, R.; Carrero, J.J.; Carvalho, F.; Castañeda-Orjuela, C.A.; Castro, F.; Catalá-López, F.; Cerin, E.; Chaiah, Y.; Chang, J-C.; Chatziralli, I.; Chiang, P.P-C.; Christensen, H.; Christopher, D.J.; Cooper, C.; Cortesi, P.A.; Costa, V.M.; Criqui, M.H.; Crowe, C.S.; Damasceno, A.A.M.; Daryani, A.; De la Cruz-Góngora, V.; De la Hoz, F.P.; De Leo, D.; Demoz, G.T.; Deribe, K.; Dharmaratne, S.D.; Diaz, D.; Dinberu, M.T.; Djalalinia, S.; Doku, D.T.; Dubey, M.; Dubljanin, E.; Duken, E.E.; Edvardsson, D.; El-Khatib, Z.; Endres, M.; Endries, A.Y.; Eskandarieh, S.; Esteghamati, A.; Esteghamati, S.; Farhadi, F.; Faro, A.; Farzadfar, F.; Farzaei, M.H.; Fatima, B.; Fereshtehnejad, S-M.; Fernandes, E.; Feyissa, G.T.; Filip, I.; Fischer, F.; Fukumoto, T.; Ganji, M.; Gankpe, F.G.; Garcia-Gordillo, M.A.; Gebre, A.K.; Gebremichael, T.G.; Gelaw, B.K.; Geleijnse, J.M.; Geremew, D.; Gezae, K.E.; Ghasemi-Kasman, M.; Gidey, M.Y.; Gill, P.S.; Gill, T.K.; Girma, E.T.; Gnedovskaya, E.V.; Goulart, A.C.; Grada, A.; Grosso, G.; Guo, Y.; Gupta, R.; Gupta, R.; Haagsma, J.A.; Hagos, T.B.; Haj-Mirzaian, A.; Haj-Mirzaian, A.; Hamadeh, R.R.; Hamidi, S.; Hankey, G.J.; Hao, Y.; Haro, J.M.; Hassankhani, H.; Hassen, H.Y.; Havmoeller, R.; Hay, S.I.; Hegazy, M.I.; Heidari, B.; Henok, A.; Heydarpour, F.; Hoang, C.L.; Hole, M.K.; Homaie Rad, E.; Hosseini, S.M.; Hu, G.; Igumbor, E.U.; Ilesanmi, O.S.; Irvani, S.S.N.; Islam, S.M.S.; Jakovljevic, M.; Javanbakht, M.; Jha, R.P.; Jobanputra, Y.B.; Jonas, J.B.; Jozwiak, J.J.; Jürisson, M.; Kahsay, A.; Kalani, R.; Kalkonde, Y.; Kamil, T.A.; Kanchan, T.; Kara-mi, M.; Karch, A.; Karimi, N.; Kasaeian, A.; Kassa, T.D.; Kassa, Z.Y.; Kaul, A.; Kefale, A.T.; Keiyoro, P.N.; Khader, Y.S.; Khafaie, M.A.; Khalil, I.A.; Khan, E.A.; Khang, Y-H.; Khazaie, H.; Kiadaliri, A.A.; Kiirithio, D.N.; Kim, A.S.; Kim, D.; Kim, Y-E.; Kim, Y.J.; Kisa, A.; Kokubo, Y.; Koyanagi, A.; Krishnamurthi, R.V.; Kuate Defo, B.; Kucuk Bicer, B.; Kumar, M.; Lacey, B.; Lafranconi, A.; Lansingh, V.C.; Latifi, A.; Leshargie, C.T.; Li, S.; Liao, Y.; Linn, S.; Lo, W.D.; Lopez, J.C.F.; Lorkowski, S.; Lotufo, P.A.; Lucas, R.M.; Lunevicius, R.; Mackay, M.T.; Mahotra, N.B.; Majdan, M.; Majdzadeh, R.; Majeed, A.; Malekzadeh, R.; Malta, D.C.; Manafi, N.; Mansournia, M.A.; Mantovani, L.G.; März, W.; Mashamba-Thompson, T.P.; Massenburg, B.B.; Mate, K.K.V.; McAlinden, C.; McGrath, J.J.; Mehta, V.; Meier, T.; Meles, H.G.; Melese, A.; Memiah, P.T.N.; Memish, Z.A.; Mendoza, W.; Mengistu, D.T.; Mengistu, G.; Meretoja, A.; Meretoja, T.J.; Mestrovic, T.; Miazgowski, B.; Miazgowski, T.; Miller, T.R.; Mini, G.K.; Mirrakhimov, E.M.; Moazen, B.; Mohajer, B.; Mohammad Gholi Mezerji, N.; Mohammadi, M.; Mohammadi-Khanaposhtani, M.; Mohammadibakhsh, R.; Mo-hammadnia-Afrouzi, M.; Mohammed, S.; Mohebi, F.; Mokdad, A.H.; Monasta, L.; Mondello, S.; Moodley, Y.; Moosazadeh, M.; Moradi, G.; Moradi-Lakeh, M.; Moradinazar, M.; Moraga, P.; Moreno Velásquez, I.; Morrison, S.D.; Mousavi, S.M.; Muhammed, O.S.; Muruet, W.; Musa, K.I.; Mustafa, G.; Naderi, M.; Nagel, G.; Naheed, A.; Naik, G.; Najafi, F.; Nangia, V.; Negoi, I.; Negoi, R.I.; Newton, C.R.J.; Ngunjiri, J.W.; Nguyen, C.T.; Nguyen, L.H.; Ningrum, D.N.A.; Nirayo, Y.L.; Nixon, M.R.; Norrving, B.; Noubiap, J.J.; Nourollahpour Shiadeh, M.; Nyasulu, P.S.; Ogah, O.S.; Oh, I-H.; Olagunju, A.T.; Olagunju, T.O.; Olivares, P.R.; Onwujekwe, O.E.; Oren, E.; Owolabi, M.O.; Pa, M.; Pakpour, A.H.; Pan, W-H.; Panda-Jonas, S.; Pandian, J.D.; Patel, S.K.; Pereira, D.M.; Petzold, M.; Pillay, J.D.; Piradov, M.A.; Polanczyk, G.V.; Polinder, S.; Postma, M.J.; Poulton, R.; Poustchi, H.; Prakash, S.; Prakash, V.; Qorbani, M.; Radfar, A.; Rafay, A.; Rafiei, A.; Rahim, F.; Rahimi-Movaghar, V.; Rahman, M.; Rahman, M.H.U.; Rahman, M.A.; Rajati, F.; Ram, U.; Ranta, A.; Rawaf, D.L.; Rawaf, S.; Reinig, N.; Reis, C.; Renzaho, A.M.N.; Resnikoff, S.; Rezaeian, S.; Rezai, M.S.; Rios González, C.M.; Roberts, N.L.S.; Roever, L.; Ronfani, L.; Roro, E.M.; Roshandel, G.; Rostami, A.; Sabbagh, P.; Sacco, R.L.; Sachdev, P.S.; Saddik, B.; Safari, H.; Safari-Faramani, R.; Safi, S.; Safiri, S.; Sagar, R.; Sahathevan, R.; Sahebkar, A.; Sahraian, M.A.; Salamati, P.; Salehi Zahabi, S.; Salimi, Y.; Samy, A.M.; Sanabria, J.; Santos, I.S.; Santric Milicevic, M.M.; Sarrafzadegan, N.; Sartorius, B.; Sarvi, S.; Sathian, B.; Satpathy, M.; Sawant, A.R.; Sawhney, M.; Schneider, I.J.C.; Schöttker, B.; Schwebel, D.C.; Seedat, S.; Sepanlou, S.G.; Shabaninejad, H.; Shafieesabet, A.; Shaikh, M.A.; Shakir, R.A.; Shams-Beyranvand, M.; Shamsizadeh, M.; Sharif, M.; Sharif-Alhoseini, M.; She, J.; Sheikh, A.; Sheth, K.N.; Shigematsu, M.; Shiri, R.; Shirkoohi, R.; Shiue, I.; Siabani, S.; Siddiqi, T.J.; Sigfusdottir, I.D.; Sigurvinsdottir, R.; Silberberg, D.H.; Silva, J.P.; Silveira, D.G.A.; Singh, J.A.; Sinha, D.N.; Skiadaresi, E.; Smith, M.; Sobaih, B.H.; Sobhani, S.; Soofi, M.; Soyiri, I.N.; Sposato, L.A.; Stein, D.J.; Stein, M.B.; Stokes, M.A.; Sufiyan, M.B.; Sykes, B.L.; Sylaja, P.N.; Tabarés-Seisdedos, R.; Te Ao, B.J.; Tehrani-Banihashemi, A.; Temsah, M-H.; Temsah, O.; Thakur, J.S.; Thrift, A.G.; Topor-Madry, R.; Tortajada-Girbés, M.; Tovani-Palone, M.R.; Tran, B.X.; Tran, K.B.; Truelsen, T.C.; Tsadik, A.G.; Tudor Car, L.; Ukwaja, K.N.; Ullah, I.; Usman, M.S.; Uthman, O.A.; Valdez, P.R.; Vasankari, T.J.; Vasanthan, R.; Veisani, Y.; Venketasubramanian, N.; Violante, F.S.; Vlassov, V.; Vosoughi, K.; Vu, G.T.; Vujcic, I.S.; Wagnew, F.S.; Waheed, Y.; Wang, Y-P.; Weiderpass, E.; Weiss, J.; Whiteford, H.A.; Wijeratne, T.; Winkler, A.S.; Wiysonge, C.S.; Wolfe, C.D.A.; Xu, G.; Yadollahpour, A.; Yamada, T.; Yano, Y.; Yaseri, M.; Yatsuya, H.; Yimer, E.M.; Yip, P.; Yisma, E.; Yonemoto, N.; Yousefifard, M.; Yu, C.; Zaidi, Z.; Zaman, S.B.; Zamani, M.; Zandian, H.; Zare, Z.; Zhang, Y.; Zodpey, S.; Naghavi, M.; Murray, C.J.L.; Vos, T. Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol., 2019, 18(5), 459-480.
[http://dx.doi.org/10.1016/S1474-4422(18)30499-X]

Kowal, S.L.; Dall, T.M.; Chakrabarti, R.; Storm, M.V.; Jain, A. The current and projected economic burden of Parkinson’s disease in the United States. Mov. Disord., 2013, 28(3), 311-318.
[http://dx.doi.org/10.1002/mds.25292]

Dorsey, E.R.; Constantinescu, R.; Thompson, J.P.; Biglan, K.M.; Holloway, R.G.; Kieburtz, K.; Marshall, F.J.; Ravina, B.M.; Schifitto, G.; Siderowf, A.; Tanner, C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 2007, 68(5), 384-386.
[http://dx.doi.org/10.1212/01.wnl.0000247740.47667.03]

Ammar, A.; Trabelsi, K.; Hermassi, S.; Kolahi, A.A.; Mansournia, M.; Jahrami, H.; Boukhris, O.; Boujelbane, M.; Glenn, J.; Clark, C.; Nejadghaderi, A.; Puce, L.; Safiri, S.; Chtourou, H.; Schöllhorn, W.; Zmijewski, P.; Bragazzi, N. Global disease burden attributed to low physical activity in 204 countries and territories from 1990 to 2019: Insights from the global burden of disease 2019 study. Biol. Sport, 2023, 40(3), 835-855.
[http://dx.doi.org/10.5114/biolsport.2023.121322]

Lonikar, N.; Choudhari, P.; Bhusnuare, O. In silico analysis of marine indole alkaloids for design of adenosine A2A receptor antagonist. J. Biomol. Struct. Dyn., 2021, 39(10), 3515-3522.
[http://dx.doi.org/10.1080/07391102.2020.1765874]

German, D.C.; Manaye, K.; Smith, W.K.; Woodward, D.J.; Saper, C.B. Midbrain dopaminergic cell loss in parkinson’s disease: Computer visualization. Ann. Neurol., 1989, 26(4), 507-514.
[http://dx.doi.org/10.1002/ana.410260403]

Lotharius, J.; Brundin, P. Pathogenesis of parkinson’s disease: Dopamine, vesicles and α-synuclein. Nat. Rev. Neurosci., 2002, 3(12), 932-942.
[http://dx.doi.org/10.1038/nrn983]

Gottwald, M.D.; Aminoff, M.J. New frontiers in the pharmacological management of Parkinson's disease. Drugs Today., 2008, 44(7), 531-545.
[http://dx.doi.org/10.1358/dot.2008.44.7.1217105]

Simuni, T.; Jaggi, J.L.; Mulholland, H.; Hurtig, H.I.; Colcher, A.; Siderowf, A.D.; Ravina, B.; Skolnick, B.E.; Goldstein, R.; Stern, M.B.; Baltuch, G.H. Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: A study of efficacy and safety. J. Neurosurg., 2002, 96(4), 666-672.
[http://dx.doi.org/10.3171/jns.2002.96.4.0666]

Ansah, T.A.; Ferguson, M.C.; Nayyar, T.; Deutch, A.Y. Age- and duration-dependent effects of MPTP on cortical serotonin systems. Neurosci. Lett., 2011, 504(2), 160-164.
[http://dx.doi.org/10.1016/j.neulet.2011.09.026]

Jankovic, J. Parkinson’s disease: Clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry, 2008, 79(4), 368-376.
[http://dx.doi.org/10.1136/jnnp.2007.131045]

Hurley, M.J.; Brandon, B.; Gentleman, S.M.; Dexter, D.T. Parkinson’s disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain, 2013, 136(7), 2077-2097.
[http://dx.doi.org/10.1093/brain/awt134]

Błaszczyk, J.W. Parkinson’s disease and neurodegeneration: GABA-collapse hypothesis. Front. Neurosci., 2016, 10, 269.
[http://dx.doi.org/10.3389/fnins.2016.00269]

Aosaki, T.; Miura, M.; Suzuki, T.; Nishimura, K.; Masuda, M. Acetylcholine-dopamine balance hypothesis in the striatum: An update. Geriatr. Gerontol. Int., 2010, 10, S148-S157.
[http://dx.doi.org/10.1111/j.1447-0594.2010.00588.x]

Stefanis, L. α-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med., 2012, 2(2), a009399.
[http://dx.doi.org/10.1101/cshperspect.a009399]

Mouradian, M.M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology, 2002, 58(2), 179-185.
[http://dx.doi.org/10.1212/WNL.58.2.179]

Dauer, W.; Kholodilov, N.; Vila, M.; Trillat, A.C.; Goodchild, R.; Larsen, K.E.; Staal, R.; Tieu, K.; Schmitz, Y.; Yuan, C.A.; Rocha, M.; Jackson-Lewis, V.; Hersch, S.; Sulzer, D.; Przedborski, S.; Burke, R.; Hen, R. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA, 2002, 99(22), 14524-14529.
[http://dx.doi.org/10.1073/pnas.172514599]

Ostrerova-Golts, N.; Petrucelli, L.; Hardy, J.; Lee, J.M.; Farer, M.; Wolozin, B. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci., 2000, 20(16), 6048-6054.
[http://dx.doi.org/10.1523/JNEUROSCI.20-16-06048.2000]

Fowler, J.S.; Volkow, N.D.; Wang, G.J.; Logan, J.; Pappas, N.; Shea, C.; MacGregor, R. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol. Aging, 1997, 18(4), 431-435.
[http://dx.doi.org/10.1016/S0197-4580(97)00037-7]

Andrei, C.; Dazzi, C.; Lotti, L.; Torrisi, M.R.; Chimini, G.; Rubartelli, A. The secretory route of the leaderless protein interleukin 1β involves exocytosis of endolysosome-related vesicles. Mol. Biol. Cell, 1999, 10(5), 1463-1475.
[http://dx.doi.org/10.1091/mbc.10.5.1463]

Zhou, S.; Schuetz, J.D.; Bunting, K.D.; Colapietro, A.M.; Sampath, J.; Morris, J.J.; Lagutina, I.; Grosveld, G.C.; Osawa, M.; Nakauchi, H.; Sorrentino, B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med., 2001, 7(9), 1028-1034.
[http://dx.doi.org/10.1038/nm0901-1028]

Flieger, O.; Engling, A.; Bucala, R.; Lue, H.; Nickel, W.; Bernhagen, J. Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett., 2003, 551(1-3), 78-86.
[http://dx.doi.org/10.1016/S0014-5793(03)00900-1]

Loebinger, M.R.; Giangreco, A.; Groot, K.R.; Prichard, L.; Allen, K.; Simpson, C.; Bazley, L.; Navani, N.; Tibrewal, S.; Davies, D.; Janes, S.M. Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter block-ade. Br. J. Cancer, 2008, 98(2), 380-387.
[http://dx.doi.org/10.1038/sj.bjc.6604185]

Frye, B.C.; Halfter, S.; Djudjaj, S.; Muehlenberg, P.; Weber, S.; Raffetseder, U.; En-Nia, A.; Knott, H.; Baron, J.M.; Dooley, S.; Bernhagen, J.; Mertens, P.R. Y‐box protein‐1 is actively secreted through a non‐classical pathway and acts as an extracellular mitogen. EMBO Rep., 2009, 10(7), 783-789.
[http://dx.doi.org/10.1038/embor.2009.81]

Maiti, P.; Manna, J.; Dunbar, G.L. Current understanding of the molecular mechanisms in Parkinson’s disease: Targets for potential treatments. Transl. Neurodegener., 2017, 6(1), 28.
[http://dx.doi.org/10.1186/s40035-017-0099-z]

Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. nature, 1998, 392(6676), 605-608.
[http://dx.doi.org/10.1038/33416]

Bouhouche, A.; Tibar, H.; Ben El Haj, R.; El Bayad, K.; Razine, R.; Tazrout, S.; Skalli, A.; Bouslam, N.; Elouardi, L.; Benomar, A.; Yahyaoui, M.; Regragui, W. LRRK2 G2019S mutation: Prevalence and clinical features in moroccans with Parkinson’s disease. Parkinsons Dis., 2017, 2017, 1-7.
[http://dx.doi.org/10.1155/2017/2412486]

Rubinsztein, D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature, 2006, 443(7113), 780-786.
[http://dx.doi.org/10.1038/nature05291]

Chan, N.C.; Salazar, A.M.; Pham, A.H.; Sweredoski, M.J.; Kolawa, N.J.; Graham, R.L.J.; Hess, S.; Chan, D.C. Broad activation of the ubiquitin–proteasome system by Parkin is critical for mitophagy. Hum. Mol. Genet., 2011, 20(9), 1726-1737.
[http://dx.doi.org/10.1093/hmg/ddr048]

Dokladny, K.; Myers, O.B.; Moseley, P.L. Heat shock response and autophagy—cooperation and control. Autophagy, 2015, 11(2), 200-213.
[http://dx.doi.org/10.1080/15548627.2015.1009776]

Maiti, P.; Manna, J.; Veleri, S.; Frautschy, S. Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin. BioMed Res. Int., 2014, 2014, 1-14.
[http://dx.doi.org/10.1155/2014/495091]

Wyttenbach, A. Role of heat shock proteins during polyglutamine neurodegeneration. J. Mol. Neurosci., 2004, 23(1-2), 069-096.
[http://dx.doi.org/10.1385/JMN:23:1-2:069]

Parker, W.D., Jr; Parks, J.K.; Swerdlow, R.H. Complex I deficiency in Parkinson’s disease frontal cortex. Brain Res., 2008, 1189, 215-218.
[http://dx.doi.org/10.1016/j.brainres.2007.10.061]

Cannon, J.R.; Tapias, V.; Na, H.M.; Honick, A.S.; Drolet, R.E.; Greenamyre, J.T. A highly reproducible rotenone model of Parkinson’s disease. Neurobiol. Dis., 2009, 34(2), 279-290.
[http://dx.doi.org/10.1016/j.nbd.2009.01.016]

Anderson, G.; Noorian, A.; Taylor, G.; Anitha, M.; Bernhard, D.; Srinivasan, S.; Greene, J. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson’s disease. Exp. Neurol., 2007, 207(1), 4-12.
[http://dx.doi.org/10.1016/j.expneurol.2007.05.010]

Bezard, E.; Dovero, S.; Bioulac, B.; Gross, C.E. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci. Lett., 1997, 234(1), 47-50.
[http://dx.doi.org/10.1016/S0304-3940(97)00663-0]

Mark, L.P.; Prost, R.W.; Ulmer, J.L.; Smith, M.M.; Daniels, D.L.; Strottmann, J.M.; Brown, W.D.; Hacein-Bey, L. Pictorial review of glutamate excitotoxicity: Fundamental concepts for neuroimaging. AJNR Am. J. Neuroradiol., 2001, 22(10), 1813-1824.
[PMID: 11733308]

Dong, X.; Wang, Y.; Qin, Z. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin., 2009, 30(4), 379-387.
[http://dx.doi.org/10.1038/aps.2009.24]

Paisán-Ruíz, C.; Jain, S.; Evans, E.W.; Gilks, W.P.; Simón, J.; van der Brug, M.; de Munain, A.L.; Aparicio, S.; Gil, A.M.; Khan, N.; Johnson, J.; Martinez, J.R.; Nicholl, D.; Carrera, I.M.; Peňa, A.S.; de Silva, R.; Lees, A.; Martí-Massó, J.F.; Pérez-Tur, J.; Wood, N.W.; Singleton, A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron, 2004, 44(4), 595-600.
[http://dx.doi.org/10.1016/j.neuron.2004.10.023]

Galter, D.; Westerlund, M.; Carmine, A.; Lindqvist, E.; Sydow, O.; Olson, L. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol., 2006, 59(4), 714-719.
[http://dx.doi.org/10.1002/ana.20808]

Hauser, R.A.; Freeman, T.B.; Snow, B.J.; Nauert, M.; Gauger, L.; Kordower, J.H.; Olanow, C.W. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol., 1999, 56(2), 179-187.
[http://dx.doi.org/10.1001/archneur.56.2.179]

Polymeropoulos, M.H.; Higgins, J.J.; Golbe, L.I.; Johnson, W.G.; Ide, S.E.; Di Iorio, G.; Sanges, G.; Stenroos, E.S.; Pho, L.T.; Schaffer, A.A.; Lazzarini, A.M.; Nussbaum, R.L.; Duvoisin, R.C. Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Sci., 1996, 274(5290), 1197-1199.
[http://dx.doi.org/10.1126/science.274.5290.1197]

Kuhla, A.; Ludwig, S.C.; Kuhla, B.; Münch, G.; Vollmar, B. Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer’s disease brain. Neurobiol. Aging, 2015, 36(2), 753-761.
[http://dx.doi.org/10.1016/j.neurobiolaging.2014.09.025]

Ip, C.W.; Klaus, L.C.; Karikari, A.A.; Visanji, N.P.; Brotchie, J.M.; Lang, A.E.; Volkmann, J.; Koprich, J.B. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: A new mouse model for Parkinson’s disease. Acta Neuropathol. Commun., 2017, 5(1), 11.
[http://dx.doi.org/10.1186/s40478-017-0416-x]

Richfield, E.K.; Thiruchelvam, M.J.; Cory-Slechta, D.A.; Wuertzer, C.; Gainetdinov, R.R.; Caron, M.G.; Di Monte, D.A.; Federoff, H.J. Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp. Neurol., 2002, 175(1), 35-48.
[http://dx.doi.org/10.1006/exnr.2002.7882]

Jeon, M.Y.; Lee, W.Y.; Kang, H.Y.; Chung, E.J. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models. Neurol. Res., 2007, 29(3), 289-295.
[http://dx.doi.org/10.1179/174313206X153996]

Barbeau, A. L-dopa therapy in Parkinson’s disease: A critical review of nine years’ experience. Can. Med. Assoc. J., 1969, 101(13), 59.
[PMID: 4903690]

Foster, H.D.; Hoffer, A. The two faces of L-DOPA: Benefits and adverse side effects in the treatment of Encephalitis lethargica, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis. Med. Hypotheses, 2004, 62(2), 177-181.
[http://dx.doi.org/10.1016/S0306-9877(03)00318-9]

Cenci, M.A. Presynaptic mechanisms of l-DOPA-induced dyskinesia: The findings, the debate, and the therapeutic implications. Front. Neurol., 2014, 5, 242.
[http://dx.doi.org/10.3389/fneur.2014.00242]

Korczyn, A.D. Drug treatment of Parkinson’s disease. Dialogues Clin. Neurosci., 2022, 6(3), 315-322.
[http://dx.doi.org/10.31887/DCNS.2004.6.3/akorczyn]

Antonini, A.; Abbruzzese, G.; Barone, P.; Bonuccelli, U.; Lopiano, L.; Onofrj, M.; Zappia, M.; Quattrone, A. COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): Relevance for motor and non-motor features. Neuropsychiatr. Dis. Treat., 2008, 4(1), 1.
[http://dx.doi.org/10.2147/NDT.S2404]

Brooks, D.J. Dopamine agonists: Their role in the treatment of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 2000, 68(6), 685-689.
[http://dx.doi.org/10.1136/jnnp.68.6.685]

Tintner, R.; Jankovic, J. Dopamine agonists in Parkinson’s disease. Expert Opin. Investig. Drugs, 2003, 12(11), 1803-1820.
[http://dx.doi.org/10.1517/13543784.12.11.1803]

Jankovic, J.; Aguilar, L.G. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr. Dis. Treat., 2008, 4(4), 743-757.
[http://dx.doi.org/10.2147/NDT.S2006]

Chen, J.J.; Marsh, L. Anxiety in Parkinson’s disease: Identification and management. Ther. Adv. Neurol. Disord., 2014, 7(1), 52-59.
[http://dx.doi.org/10.1177/1756285613495723]

Durif, F.; Debilly, B.; Galitzky, M.; Morand, D.; Viallet, F.; Borg, M.; Thobois, S.; Broussolle, E.; Rascol, O. Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study. Neurology, 2004, 62(3), 381-388.
[http://dx.doi.org/10.1212/01.WNL.0000110317.52453.6C]

Huffman, J.C.; Alpert, J.E. An approach to the psychopharmacologic care of patients: Antidepressants, antipsychotics, anxiolytics, mood stabilizers, and natural remedies. Med. Clin. North Am., 2010, 94(6), 1141-1160.
[http://dx.doi.org/10.1016/j.mcna.2010.08.009]

Wink, M. In Alkaloids; Springer, 1998, pp. 11-44.
[http://dx.doi.org/10.1007/978-1-4757-2905-4_2]

Roberts, M.F. Alkaloids: Biochemistry, ecology, and medicinal applications; Springer Science & Business Media, 2013.
[http://dx.doi.org/10.1007/978-1-4757-2905-4]

Dey, P.; Kundu, A.; Kumar, A.; Gupta, M.; Lee, B.M.; Bhakta, T.; Dash, S.; Kim, H.S. Chapter 15: Analysis of alkaloids (indole alkaloids, isoquinoline alkaloids, tropane alkaloids).in Recent advances in natural products analysis; Elsevier, 2020, pp. 505-567.
[http://dx.doi.org/10.1016/B978-0-12-816455-6.00015-9]

Connolly, J.; Hill, R.; Robinson, J. Advances in flavours and fragrances. Dictionary of Terpenoids; Chapman & Hall: London, 1991, pp. 677-736.
[http://dx.doi.org/10.1007/978-1-4899-4513-6]

Talapatra, S.K.; Talapatra, B. Alkaloids. general introduction.In Chemistry of Plant Natural Products; Springer, 2015, pp. 717-724.
[http://dx.doi.org/10.1007/978-3-642-45410-3_15]

Henning, C.P. Compuestos secundarios nitrogenados: Alcaloides; Productos Naturales Vegetales, 2013, p. 18.

Gao, F.; Li, Y.Y.; Wang, D.; Huang, X.; Liu, Q. Diterpenoid alkaloids from the Chinese traditional herbal Fuzi and their cytotoxic activity. Molecules, 2012, 17(5), 5187-5194.
[http://dx.doi.org/10.3390/molecules17055187]

Wang, F.P.; Chen, Q.H.; Liu, X.Y. Diterpenoid alkaloids. Nat. Prod. Rep., 2010, 27(4), 529-570.
[http://dx.doi.org/10.1039/b916679c]

Borzeix, M.; Cahn, J. Cerebral antioedematous effect of Teproside and of some vincamine derivatives. Int. J. Clin. Pharmacol., 1984, 4(4), 259-261.
[PMID: 6500773]

Ng, Y.P.; Or, T.C.T.; Ip, N.Y. Plant alkaloids as drug leads for Alzheimer’s disease. Neurochem. Int., 2015, 89, 260-270.
[http://dx.doi.org/10.1016/j.neuint.2015.07.018]

Amirkia, V.; Heinrich, M. Alkaloids as drug leads – A predictive structural and biodiversity-based analysis. Phytochem. Lett., 2014, 10, xlviii-liii.
[http://dx.doi.org/10.1016/j.phytol.2014.06.015]

Dey, A. Plant-derived alkaloids: A promising window for neuroprotective drug discovery. In: Discovery and development of neuroprotective agents from natural products; Elsevier, 2018; pp. 237-320.
[http://dx.doi.org/10.1016/B978-0-12-809593-5.00006-9]

Cushnie, T.P.T.; Cushnie, B.; Lamb, A.J. Alkaloids: An overview of their antibacterial, antibiotic-enhancing and antivirulence activities. Int. J. Antimicrob. Agents, 2014, 44(5), 377-386.
[http://dx.doi.org/10.1016/j.ijantimicag.2014.06.001]

Cortes, N.; Posada-Duque, R.A.; Alvarez, R.; Alzate, F.; Berkov, S.; Cardona-Gómez, G.P.; Osorio, E. Neuroprotective activity and acetylcholinesterase inhibition of five Amaryllidaceae species: A comparative study. Life Sci., 2015, 122, 42-50.
[http://dx.doi.org/10.1016/j.lfs.2014.12.011]

Estévez, V.; Villacampa, M.; Menéndez, J.C. Recent advances in the synthesis of pyrroles by multicomponent reactions. Chem. Soc. Rev., 2014, 43(13), 4633-4657.
[http://dx.doi.org/10.1039/C3CS60015G]

Kaur, R.; Arora, S. Alkaloids-important therapeutic secondary metabolites of plant origin. J. Crit. Rev., 2015, 2(3), 1-8.

Gutiérrez-Grijalva, E.P.; López-Martínez, L.X.; Contreras-Angulo, L.A.; Elizalde-Romero, C.A.; Heredia, J.B. Plant Alkaloids: Structures and bioactive properties. Plant-derived bioactives; Springer, 2020, pp. 85-117.
[http://dx.doi.org/10.1007/978-981-15-2361-8_5]

Goel, P.; Alam, O.; Naim, M.J.; Nawaz, F.; Iqbal, M.; Alam, M.I. Recent advancement of piperidine moiety in treatment of cancer- A review. Eur. J. Med. Chem., 2018, 157, 480-502.
[http://dx.doi.org/10.1016/j.ejmech.2018.08.017]

Koleva, I.I.; van Beek, T.A.; Soffers, A.E.M.F.; Dusemund, B.; Rietjens, I.M.C.M. Alkaloids in the human food chain - Natural occurrence and possible adverse effects. Mol. Nutr. Food Res., 2012, 56(1), 30-52.
[http://dx.doi.org/10.1002/mnfr.201100165]

Mao, Z.; Huang, S.; Gao, L.; Wang, A.; Huang, P. A novel and versatile method for the enantioselective syntheses of tropane alkaloids. Sci. China Chem., 2014, 57(2), 252-264.
[http://dx.doi.org/10.1007/s11426-013-4998-2]

Jirschitzka, J.; Schmidt, G.W.; Reichelt, M.; Schneider, B.; Gershenzon, J.; D’Auria, J.C. Plant tropane alkaloid biosynthesis evolved independently in the Solanaceae and Erythroxylaceae. Proc. Natl. Acad. Sci. USA, 2012, 109(26), 10304-10309.
[http://dx.doi.org/10.1073/pnas.1200473109]

Byler, K.G.; Wang, C.; Setzer, W.N. Quinoline alkaloids as intercalative topoisomerase inhibitors. J. Mol. Model., 2009, 15(12), 1417-1426.
[http://dx.doi.org/10.1007/s00894-009-0501-6]

Cai, X.H.; Li, Y.; Su, J.; Liu, Y.P.; Li, X.N.; Luo, X.D. Novel indole and quinoline alkaloids from Melodinus yunnanensis. Nat. Prod. Bioprospect., 2011, 1(1), 25-28.
[http://dx.doi.org/10.1007/s13659-011-0001-0]

Khan, A.Y.; Suresh Kumar, G. Natural isoquinoline alkaloids: Binding aspects to functional proteins, serum albumins, hemoglobin, and lysozyme. Biophys. Rev., 2015, 7(4), 407-420.
[http://dx.doi.org/10.1007/s12551-015-0183-5]

Bhadra, K.; Kumar, G.S. Therapeutic potential of nucleic acid-binding isoquinoline alkaloids: Binding aspects and implications for drug design. Med. Res. Rev., 2011, 31(6), 821-862.
[http://dx.doi.org/10.1002/med.20202]

Szőke, É.; Lemberkovics, É.; Kursinszki, L. Alkaloids derived from lysine: Piperidine alkaloids; Natu. Produc, 2013, pp. 303-341.
[http://dx.doi.org/10.1007/978-3-642-22144-6_10]

Guirimand, G.; Courdavault, V.; St-Pierre, B.; Burlat, V. Biosynthesis and regulation of alkaloids. In: Plant developmental biology-biotechnological perspectives; Springer, 2010; pp. 139-160.
[http://dx.doi.org/10.1007/978-3-642-04670-4_8]

Sagi, S.; Avula, B.; Wang, Y.H.; Khan, I.A. Quantification and characterization of alkaloids from roots of Rauwolfia serpentina using ultra-high performance liquid chromatography-photo diode array-mass spectrometry. Anal. Bioanal. Chem., 2016, 408(1), 177-190.
[http://dx.doi.org/10.1007/s00216-015-9093-4]

Silva, V.G.; Silva, R.O.; Damasceno, S.R.B.; Carvalho, N.S.; Prudêncio, R.S.; Aragão, K.S.; Guimarães, M.A.; Campos, S.A.; Véras, L.M.C.; Godejohann, M.; Leite, J.R.S.A.; Barbosa, A.L.R.; Medeiros, J-V.R. Anti-inflammatory and antinociceptive activity of epiisopiloturine, an imidazole alkaloid isolated from Pilocarpus microphyllus. J. Nat. Prod., 2013, 76(6), 1071-1077.
[http://dx.doi.org/10.1021/np400099m]

Debnath, B.; Singh, W.S.; Das, M.; Goswami, S.; Singh, M.K.; Maiti, D.; Manna, K. Role of plant alkaloids on human health: A review of biological activities. Mater. Today Chem., 2018, 9, 56-72.
[http://dx.doi.org/10.1016/j.mtchem.2018.05.001]

Davis, R.A.; Carroll, A.R.; Quinn, R.J. Eudistomin V, a new β-Carboline from the Australian ascidian Pseudodistoma aureum. J. Nat. Prod., 1998, 61(7), 959-960.
[http://dx.doi.org/10.1021/np9800452]

Klein-Júnior, L.C.; Cretton, S.; Vander Heyden, Y.; Gasper, A.L.; Nejad-Ebrahimi, S.; Christen, P.; Henriques, A.T. Bioactive azepine-indole alkaloids from Psychotria nemorosa. J. Nat. Prod., 2020, 83(4), 852-863.
[http://dx.doi.org/10.1021/acs.jnatprod.9b00469]

Schmidt, F.; Douaron, G.L.; Champy, P.; Amar, M.; Séon-Méniel, B.; Raisman-Vozari, R.; Figadère, B. Tryptamine-derived alkaloids from Annonaceae exerting neurotrophin-like properties on primary dopaminergic neurons. Bioorg. Med. Chem., 2010, 18(14), 5103-5113.
[http://dx.doi.org/10.1016/j.bmc.2010.05.067]

dos Santos Passos, C.; Klein-Júnior, L.C.; de Mello Andrade, J.M.; Matté, C.; Henriques, A.T. The catechol-O-methyltransferase inhibitory potential of Z-vallesiachotamine by in silico and in vitro approaches. Rev. Bras. Farmacogn., 2015, 25(4), 382-386.
[http://dx.doi.org/10.1016/j.bjp.2015.07.002]

Kozanecka-Okupnik, W.; Jasiewicz, B.; Pospieszny, T.; Jastrząb, R.; Skrobańska, M.; Mrówczyńska, L. Spectroscopy, molecular modeling and anti-oxidant activity studies on novel conjugates containing indole and uracil moiety. J. Mol. Struct., 2018, 1169, 130-137.
[http://dx.doi.org/10.1016/j.molstruc.2018.05.057]

Kumar, S.; Singh, A.; Kumar, B. Screening of monoterpene indole alkaloids in six Rauwolfia species by ultra‐high performance liquid chromatography orbitrap velos pro mass spectrometer. Separ. Sci. Plus, 2019, 2(8), 300-308.
[http://dx.doi.org/10.1002/sscp.201900029]

Sato, Y.; Oyobe, N.; Ogawa, T.; Suzuki, S.; Aoyama, H.; Nakamura, T.; Fujioka, H.; Shuto, S.; Arisawa, M. Design, synthesis, and monoamine oxidase inhibitory activity of (+)-cinchonaminone and its simplified derivatives. ACS Med. Chem. Lett., 2021, 12(9), 1464-1469.
[http://dx.doi.org/10.1021/acsmedchemlett.1c00310]

Xiao, X.; Tong, Z.; Zhang, Y.; Zhou, H.; Luo, M.; Hu, T.; Hu, P.; Kong, L.; Liu, Z.; Yu, C.; Huang, Z.; Hu, L. Novel prenylated indole alkaloids with neuroprotection on sh-sy5y cells against oxidative stress targeting Keap1–Nrf2. Mar. Drugs, 2022, 20(3), 191.
[http://dx.doi.org/10.3390/md20030191]

Li, Y-J.; Li, J.; Xie, L.; Zhou, J-Y.; Li, Q-X.; Yang, R-Y.; Liu, Y-P.; Fu, Y-H. Monoterpenoid indole alkaloids with potential neuroprotective activities from the stems and leaves of Melodinus cochinchinensis. Nat. Prod. Res., 2021, 36(20), 5181-5188.
[http://dx.doi.org/10.1080/14786419.2021.1922406]

Krishnan, N.; Mariappanadar, V.; Dhanabalan, A.K.; Devadasan, V.; Gopinath, S.C.B.; Raman, P. Purification, identification and in silico models of alkaloids from Nardostachys jatamansi — bioactive compounds for neurodegenerative diseases. Biomass Convers. Biorefin., 2022, 1-12.
[http://dx.doi.org/10.1007/s13399-022-03237-y]

Xu, Y.; Wang, R.; Hou, T.; Li, H.; Han, Y.; Li, Y.; Xu, L.; Lu, S.; Liu, L.; Cheng, J.; Wang, J.X.; Xu, Q.; Liu, Y.; Liang, X. Un-cariphyllin A-J, indole alkaloids from Uncaria rhynchophylla as antagonists of dopamine D2 and Mu opioid receptors. Bioorg. Chem., 2023, 130, 106257.
[http://dx.doi.org/10.1016/j.bioorg.2022.106257]

Smirnova, O.B.; Golovko, T.V.; Granik, V.G. Carbolines. Part 2: Comparison of some of the properties of α-, γ-, and δ-carbolines (Review). Pharm. Chem. J., 2011, 45(7), 389-400.
[http://dx.doi.org/10.1007/s11094-011-0641-8]

Dai, J.; Dan, W.; Schneider, U.; Wang, J. β-Carboline alkaloid monomers and dimers: Occurrence, structural diversity, and biological activities. Eur. J. Med. Chem., 2018, 157, 622-656.
[http://dx.doi.org/10.1016/j.ejmech.2018.08.027]

Herraiz, T.; Chaparro, C. Human monoamine oxidase enzyme inhibition by coffee and β-carbolines norharman and harman isolated from coffee. Life Sci., 2006, 78(8), 795-802.
[http://dx.doi.org/10.1016/j.lfs.2005.05.074]

Yang, Y.J.; Lee, J.J.; Jin, C.M.; Lim, S.C.; Lee, M.K. Effects of harman and norharman on dopamine biosynthesis and L-DOPA-induced cytotoxicity in PC12 cells. Eur. J. Pharmacol., 2008, 587(1-3), 57-64.
[http://dx.doi.org/10.1016/j.ejphar.2008.03.050]

Samoylenko, V.; Rahman, M.M.; Tekwani, B.L.; Tripathi, L.M.; Wang, Y.H.; Khan, S.I.; Khan, I.A.; Miller, L.S.; Joshi, V.C.; Muhammad, I. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease. J. Ethnopharmacol., 2010, 127(2), 357-367.
[http://dx.doi.org/10.1016/j.jep.2009.10.030]

Adayev, T.; Wegiel, J.; Hwang, Y.W. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A). Arch. Biochem. Biophys., 2011, 507(2), 212-218.
[http://dx.doi.org/10.1016/j.abb.2010.12.024]

Shalgum, A.; Govindarajulu, M.; Majrashi, M.; Ramesh, S.; Collier, W.E.; Griffin, G.; Amin, R.; Bradford, C.; Moore, T.; Dhanasekaran, M. Neuroprotective effects of Hibiscus Sabdariffa against hydrogen peroxide-induced toxicity. J. Herb. Med., 2019, 17-18, 100253.
[http://dx.doi.org/10.1016/j.hermed.2018.100253]

Nurmaganbetov, Z.S.; Arystan, L.I.; Muldaeva, G.M.; Haydargalieva, L.S.; Adekenov, S.M. Experimental study of antiparkinsonian action of the harmine hydrochloride original compound. Pharmacol. Rep., 2019, 71(6), 1050-1058.
[http://dx.doi.org/10.1016/j.pharep.2019.06.002]

Cai, C.Z.; Zhou, H.F.; Yuan, N.N.; Wu, M.Y.; Lee, S.M.Y.; Ren, J.Y.; Su, H.X.; Lu, J.J.; Chen, X.P.; Li, M.; Tan, J-Q.; Lu, J-H. Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation. Phytomedicine, 2019, 61, 152842.
[http://dx.doi.org/10.1016/j.phymed.2019.152842]

Katchborian-Neto, A.; Santos, W.T.; Nicácio, K.J.; Corrêa, J.O.A.; Murgu, M.; Martins, T.M.M.; Gomes, D.A.; Goes, A.M.; Soares, M.G.; Dias, D.F.; Chagas-Paula, D.A.; Paula, A.C.C. Neuroprotective potential of ayahuasca and untargeted metabolomics analyses: Applicability to Parkinson’s disease. J. Ethnopharmacol., 2020, 255, 112743.
[http://dx.doi.org/10.1016/j.jep.2020.112743]

Doskaliyev, A.; Seidakhmetova, R.; Tutai, D.; Goldaeva, K.; Surov, V.; Adekenov, S. S. Alkaloids of Peganum harmala L. and their pharmacological activity. Open Access Maced. J. Med. Sci., 2021, 9(A), 766-775.
[http://dx.doi.org/10.3889/oamjms.2021.6654]

Xu, J.; Ao, Y.L.; Huang, C.; Song, X.; Zhang, G.; Cui, W.; Wang, Y.; Zhang, X.Q.; Zhang, Z. Harmol promotes α-synuclein degradation and improves motor impairment in Parkinson’s models via regulating autophagy-lysosome pathway. NPJ Parkinsons Dis., 2022, 8(1), 100.
[http://dx.doi.org/10.1038/s41531-022-00361-4]

Senhaji, S.; Lamchouri, F.; Akabli, T.; Toufik, H. In vitro antioxidant activities of five β-carboline alkaloids, molecular docking, and dynamic simulations. Struct. Chem., 2022, 33(3), 883-895.
[http://dx.doi.org/10.1007/s11224-022-01886-3]